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Transient Photoreceptor Deconstruction by CNTF Enhances rAAV-
Mediated Cone Functional Rescue in Late Stage CNGB3-Achromatopsia
Abstract
Achromatopsia is a genetic disorder of cones, and one of the most common forms is a channelopathy caused
by mutations in the β-subunit, CNGB3, of the cone cyclic nucleotide-gated (CNG) channel. Recombinant
adeno-associated virus of serotype 5 (rAAV5)-mediated gene transfer of human CNGB3 cDNA to mutant
dog cones results in functional and structural rescue in dogs <0.5 years of age, but treatment is minimally
effective in dogs >1 year. We now test a new therapeutic concept by combining gene therapy with the
administration of ciliary neurotrophic factor (CNTF). Intravitreal CNTF causes transient dedifferentiation of
photoreceptors, a process called deconstruction, whereby visual cells become immature with short outer
segments, and decreased retinal function and gene expression that subsequently return to normal. Cone
function was successfully rescued in all mutant dogs treated between 14 and 42 months of age with this
strategy. CNTF-mediated deconstruction and regeneration of the photoreceptor outer segments prepares the
mutant cones optimally for gene augmentation therapy.
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Achromatopsia is a genetic disorder of cones, and one of 
the most common forms is a channelopathy caused by 
mutations in the β-subunit, CNGB3, of the cone cyclic 
nucleotide-gated (CNG) channel. Recombinant adeno-
associated virus of serotype 5 (rAAV5)-mediated gene 
transfer of human CNGB3 cDNA to mutant dog cones 
results in functional and structural rescue in dogs <0.5 
years of age, but treatment is minimally effective in dogs 
>1 year. We now test a new therapeutic concept by 
combining gene therapy with the administration of cili-
ary neurotrophic factor (CNTF). Intravitreal CNTF causes 
transient dedifferentiation of photoreceptors, a process 
called deconstruction, whereby visual cells become 
immature with short outer segments, and decreased 
retinal function and gene expression that subsequently 
return to normal. Cone function was successfully rescued 
in all mutant dogs treated between 14 and 42 months 
of age with this strategy. CNTF-mediated deconstruction 
and regeneration of the photoreceptor outer segments 
prepares the mutant cones optimally for gene augmen-
tation therapy.
Received 8 August 2012; accepted 3 March 2013; advance online  
publication 9 April 2013. doi:10.1038/mt.2013.50
INTRODUCTION
Recent breakthroughs in retinal gene therapy provide hope of 
effective treatments for inherited blinding disorders once consid-
ered incurable. For example, Leber congenital amaurosis, caused 
by loss of function of the RPE65 gene, is being successfully treated 
by delivery of RPE65 to the retinal pigment epithelium via recom-
binant adeno-associated virus (rAAV)-based vectors.1–5 This 
promising therapy evolved from proof of concept studies using 
rAAV-based viral vectors that established efficacy and preliminary 
safety in directing gene expression to the retinal pigment epithe-
lium in dogs, mice, and primates.6–9 The same technology is now 
used successfully to treat primary photoreceptor disorders in ani-
mal models, among which include achromatopsia and different 
forms of retinitis pigmentosa.10–18
Gene augmentation therapy, however, has been marginally 
effective or ineffective when the photoreceptor degeneration starts 
too early or progresses too rapidly.19–21 To circumvent this prob-
lem, rAAV vectors of different serotypes have been developed, 
e.g., rAAV8 versus rAAV5, with tyrosine-capsid mutations and/or 
self-complementary variants that minimize the interval between 
transduction and transgene expressions.18,22–24
An intermediate situation occurs when the degeneration rate is 
slow, but functional and/or structural rescue of the photoreceptor 
disease is not possible. Such is the case in CNGB3-achromatopsia, 
a channelopathy affecting cone photoreceptors in humans,25,26 
dogs,27 and mice,28 where treatment outcomes were age and dis-
ease stage dependent.10,14 In dogs, we found that successful res-
toration of cone function decreased from 11 of 14 eyes treated at 
<0.5 year of age, to 1 of 3 in those >1 year.10 The decreased rescue 
of cone function could not be explained by the absence of cones or 
the lack of CNGB3 transgene expression. As successfully treated 
cones showed localization of cyclic nucleotide-gated (CNG) chan-
nel and G-protein expression in the outer segments, in contrast to 
their absence in treated but non-functional retinas, we suspected 
that the failure possibly resulted from the improper reassembly of 
the components of the phototransduction machinery when reti-
nas were treated at later stages of disease.10
In this study, we tested the hypothesis that regenerating the 
older CNGB3-mutant cone outer segments with ciliary neuro-
trophic factor (CNTF) could enable restoration of cone pho-
totransduction following gene augmentation therapy with the 
rAAV5-PR2.1-hCNGB3 therapeutic vector. CNTF is one of the 
most studied neurotrophic factors in retinal degenerative disor-
ders and has profound effects on the retina and photoreceptors.29 
When administered intravitreally, the outer segments shorten sig-
nificantly before regrowing, and photoreceptor gene expression is 
transiently downregulated.30 Because the changes are reversible, 
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and the treated photoreceptors transiently become more imma-
ture, we have termed the process transient photoreceptor decon-
struction.31,32 Recent studies indicate that CNTF also promotes 
cone outer segment regeneration in the degenerating rat retina.33
Our present results clearly show that intravitreal injection 
of human recombinant CNTF one week before treatment with 
rAAV5-PR2.1-hCNGB3 in CNGB3-mutant dogs >1 year of age 
permitted restoration of cone function in all treated eyes, whereas 
no functional recovery was found in control eyes pretreated with 
phosphate-buffered saline (PBS). Our results provide proof of con-
cept for a novel combination therapy to facilitate restoration of cone 
function in future clinical application. They also provide an insight 
into the mechanism that mediates the assembly of CNG channels, 
and their targeting to the cone outer segments in the disease.
RESULTS
Subretinal rAAV5-PR2.1-hCNGB3 transduces older 
mutant cones but fails to restore function
Subretinal administration of the therapeutic rAAV serotype 5 
vector with hCNGB3 regulated by the full-length human red cone 
opsin promoter, rAAV5-PR2.1-hCNGB3, resulted in cone func-
tional rescue in only 1 of 10 treated eyes of mutant dogs >1 year 
of age (Table 1). This finding was the same in dogs with either 
the genomic deletion or D262N missense mutation,27 and was 
observed with treatment by subretinal injection alone (n = 3; prior 
study),10 or one week following intravitreal PBS injection (n = 7; 
Figure 1a). The failure of functional rescue was not due to lack of 
cones. Retinal flat mounts at 1 year of age showed an ~25% average 
loss of both L/M- and S-cones (Figure 2a). Loss is greater in the 
inferior and nasal quadrants, and cones are best preserved in the 
area centralis region that was targeted for treatment (Figure 2a).34 
Over a 7-year time period, we find a continuous, but slow loss 
of cones. Even in older animals, however, some intact cones with 
shortened outer segments remain, confirming previous observa-
tions (Figure 2b).35
Likewise, the lack of functional rescue in older mutants was 
not the result of low or absent transduction efficiency. When 
incorporated into the rAAV5 vector, the PR2.1 promoter results in 
specific expression of reporter gene in normal or CNGB3-mutant 
L/M cones.10,36 Furthermore, quantitative real-time PCR (qRT-
PCR) analysis of hCNGB3 expression 18 to 46 weeks after treat-
ment that resulted in no cone functional recovery showed high 
expression levels (Figure 1b), and comparable with those previ-
ously reported for successfully treated younger eyes.10
Table 1 Treatment of CNGB3-mutant dogs 
Dog ID/gender
Age  
(months) Genotype Eye
Intravitreal 
injection
Subretinal injection 
rAAV5-PR2.1-hCNGB3
ERG (weeks 
after CNTF)a
Cone  
function
Tissue analyses 
(weeks after 
CNTF)Vol (vg/ml)
M616/m 14.3 CNGB3−/− R CNTF 140 µl (4.02 × 1013) 0, 1, 6, 8.5 + qRT-PCR (27)
L PBS 160 µl (4.02 × 1013) 0, 1, 6, 8.5 − qRT-PCR (27)
M617/m 14.3 CNGB3−/− R PBS 120 µl (4.02 × 1013) 0, 1, 6, 8.5, 13 − qRT-PCR (27)
M621/f 15 CNGB3−/− R CNTF 140 µl (4.02 × 1013) 0, 1, 6 + qRT-PCR (25)
L PBS 140 µl (4.02 × 1013) 0, 1, 6 − qRT-PCR (25)
M589/m 20.8 CNGB3−/− L CNTF 180 µl (1.02 × 1013) 0, 1, 5, 11 + qRT-PCR (89)
M576/f 28.3 CNGB3−/− R CNTF 170 µl (1.17 × 1013) 1, 5b + qRT-PCR (46)
L PBS 170 µl (1.17 × 1013) 1, 5 − qRT-PCR (46)
GS83/f 42 CNGB3m/m R CNTF 200 µl (7.96 × 1011) 0, 1, 6, 10, 16 + qRT-PCR (18)
L PBS 200 µl (7.96 × 1011) 0, 1, 6, 10, 16 − qRT-PCR (18)
GS112/f 16.3 CNGB3m/m R CNTF 200 µl (7.96 × 1011) 0, 1, 6, 10, 16 + IHC (18)
L PBS 200 µl (7.96 × 1011) 0, 1, 6, 10, 16 − IHC (18)
GS115/f 16.3 CNGB3m/m R CNTF 200 µl (7.96 × 1011) 0, 1, 6, 10, 16 + qRT-PCR (18)
L PBS 200 µl (7.96 × 1011) 0, 1, 6, 10, 16 − qRT-PCR (18)
GS87/mc 13.5 CNGB3m/m R No 150 µl (7.73 × 1012) 4, 44d − qRT-PCR (44)d
GS89/fc 13.5 CNGB3m/m R No 150 µl (7.73 × 1012) 4, 68d + qRT-PCR (68)d
GS80/mc 16.5 CNGB3m/m L No 160 µl (9.43 × 1012) 4d − IHC (16)d
M635/f 13.3 CNGB3−/− R CNTF No 0, 1b + qRT-PCR (1)
L CNTF No 0, 1b + IHC (1)
M614/f 9.8 CNGB3−/− R CNTF No 1, 5b + qRT-PCR (94)
L PBS No 1, 5 − qRT-PCR (94)
GS98/m 45.4 CNGB3m/m R CNTF No 2.5, 3.5, 4.5b + IHC (7)
Gender: male (m), female (f); genotype, D262N missense mutation (CNGB3m/m), genomic deletion (CNGB3−/−); eye: right (R), left (L); intravitreal injection of either 
CNTF (12 µg in 30 µl PBS) or PBS (30 µl); ERG, electroretinography; IHC, immunohistochemistry; qRT-PCR, quantitative real-time PCR; vg, vector genomes. aTime 
points of recordable cone function are shown in boldface. bCone function was detectable in these eyes after CNTF administration alone (M635, M614, GS98), or 
before therapeutic vector injection (M576; 1 week). cTimes are after subretinal injection with therapeutic vector. dDogs also included in previous publication.10
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Intravitreal CNTF enhances rAAV5-mediated cone 
functional rescue in older mutant retinas
To determine if pretreatment with CNTF improved functional res-
cue in older retinas, we injected CNTF intravitreally 1 week before 
rAAV5-PR2.1-hCNGB3 administration in 14.3- to 42-month-old 
mutants, and assessed functional outcomes by recording the iso-
lated cone electroretinogram (ERG) responses. All seven dogs 
treated in this manner had a robust and stable recovery of cone 
function detected by 4–5 (n = 4) and 7.5–9 (n = 3) weeks after 
gene therapy (Figure 1a and Table 1). Expression of the hCNGB3 
transgene in successfully treated (CNTF and therapeutic vector) 
older mutant retinas was comparable with successfully treated 
younger eyes,10 and to retinas pretreated with PBS that showed no 
functional cone rescue (Figure 1b). Hence, the restoration of cone 
function in older CNGB3-mutant dogs is not solely depend on the 
expression of the hCNGB3 transgene mRNA.
We have not been able to determine the expression of hCNGB3 
transgene product in treated retinas as multiple antibodies pro-
duced have not been specific. However, surrogate markers of 
effective cone transduction, e.g., GNAT2, CNGA3, can be used.10 
In the normal retina, both show localization restricted to the 
outer segments, whereas in mutants, the proteins are expressed 
but delocalized from the cone outer segments.10,35,37 We find that 
restored cone function in CNTF/rAAV5-treated CNGB3-mutant 
adult retinas is associated with normal localization of both GNAT2 
and CNGA3 in cone outer segments, but this is not found in PBS/
rAAV5-treated cones (Figure 1c).
Intravitreal CNTF and reversible photoreceptor 
deconstruction
To better understand the effect of CNTF in enhancing functional 
rescue in CNGB3-mutant cones, we first examined the photore-
ceptor effects and potential signaling pathways involved in nor-
mal canine retinas (see Supplementary Table S1 for details of 
procedures). Consistent with previous observations in rodents,30 
intravitreal CNTF had a dramatic effect on retinal function, with 
decreases in both rod- and cone-mediated ERG response ampli-
tudes (Figure 3a). This effect was first noted at 3 days, peaked 
at 1 week, and recovered to normal by 5 weeks after injection 
(Figure  3b). The ERG effects corresponded temporally with 
Figure 1 Effect of intravitreal CNTF administration and subretinal rAAV5-PR2.1-hCNGB3 on the CNGB3-mutant retina. (a) Gene augmenta-
tion in a CNGB3−/−-mutant dog (28.3 months) rescues 29-Hz flicker cone responses when preceded by intravitreal CNTF injection (top row). No 
rescue of cone function was achieved when intravitreal PBS was used before gene therapy (bottom row). The dashed lines indicate stimulus onset 
and oblique arrows the individual cone-mediated flicker responses. (b) The relative amounts of retinal hCNGB3 mRNA expression were comparable 
and not significantly different when subretinal rAAV injections were preceded by either intravitreal PBS (no cone function) or CNTF (cone function). 
(c) Immunolabeling with CNGA3 and GNAT2 shows absence of cone outer segment labeling in untreated mutants (illustrated for a 10-month-old 
CNGB3m/m retina) even though L/M-cone opsin label is present. With few exceptions (arrows) cone outer segments following the treatment with PBS 
& rAAV5-PR2.1-hCNGB3 are also negative. Normal retinas and those treated with CNTF & rAAV5-PR2.1-hCNGB3 have normal outer segment immu-
nolabeling. Calibration bar = 10 µm. ACHM, achromatopsia-affected; CNTF, ciliary neurotrophic factor; msec, milli second; wt, wild-type.
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changes in photoreceptor structure and gene product expression. 
At 1 week, both rod and cone outer segments shortened dra-
matically throughout the retina. S-cones appeared more severely 
affected at the 1-week time point as hardly any S-cone outer seg-
ments were identifiable (Figure 4). Electron microscopy demon-
strated that, in addition to outer segment shortening, there was 
membrane disorganization and vesiculation of both rod and cone 
outer segments (Supplementary Figure S1). By 2 weeks, outer 
segments were longer but appeared slightly disorganized, and 
photoreceptors were normal 5 weeks after injection (Figure 4).
We then examined the gene expression levels of outer seg-
ment visual pigment proteins and CNG channel subunits of rods 
and cones, and found a marked decrease in photoreceptor gene 
expression 1 week following CNTF that appeared to fully recover 
by 2 weeks (Figure 5a,b). With the exception of S-opsin expres-
sion which was ~0.1% of the biological control group, cone-spe-
cific gene expression decreased to ~24–39% and rod-specific gene 
expression to ~14–19% at 1 week (Figure 5a,b).
We found no increased labeling of cells in normal and 
CNGB3-mutant retinas for phosphohistone-H3 (PHH3),38 rul-
ing out CNTF-induced cell proliferation. Furthermore, TUNEL 
labeling38,39 was negative following CNTF treatment, emphasizing 
that there was no cell death associated with treatment despite the 
dramatic structural changes.
As the Jak/Stat pathway is presumably activated following treat-
ment with CNTF29 in the Müller glia and photoreceptor cells that 
express the α-subunit of the CNTF receptor (CNTFRα40), we next 
assessed this pathway. Both STAT1 and STAT3 mRNA expression 
levels were elevated at 1 week, remained elevated at 2 weeks, and 
returned to normal at 5 weeks (Figure 6a). Levels of phosphory-
lated STAT1 and STAT3 were elevated at 1 week, but by 2 weeks 
had returned to baseline (pSTAT1) or remained slightly elevated 
(pSTAT3) (Figure 6b,c). CNTF also led to upregulation of STAT1 
expression at 1, 2, and 5 weeks (Figure 6b,c). In the retina, phos-
phorylated STAT was present in the vitreal margin of the inner 
nuclear layer, and in photoreceptor cells. As with western blots, 
peak expression was at 1 week, and decreased to control levels by 5 
weeks (Figure 6d). These results show that the intravitreal injection 
of CNTF in the normal canine retina results in activation of the Jak/
STAT pathway in photoreceptors and other inner nuclear layer cells.
In the mutant retina, surprisingly, we found that CNTF by 
itself also induced a partial restoration of cone function in older 
animals. One to 2.5 weeks after CNTF treatment, four of four 
eyes had low amplitude cone flicker ERG responses with pro-
longed implicit times (Table 1 and Figures 1a and 7). This effect 
was short-lived, and cone signals were lost after 5 weeks in the 
absence of staged rAAV5-PR2.1-hCNGB3 treatment (Table 1 and 
Figure 7).
In the dog, retinal development occurs postnatally with grad-
ual maturation of ERG responses.41 A similar process occurs in 
CNGB3 mutants, and immature, albeit abnormal, cone responses 
are present only between 4 and 6 weeks of age before being 
Figure 2 Changes in cones with age and disease progression. (a) Calculated loss of L/M- and S-cone densities at 1 year of age are shown sepa-
rately for four quadrants based on cone counts from selected regions of retinal flat mounts from wild-type (wt) and CNGB3−/−-mutant dogs. The 
decrease in cone density for both classes is most significant in the peripheral regions of the inferior, nasal, and superior quadrants. The loss is ≤10% 
and not significant in the area centralis located temporal to the optic disc. (b) Compared with wt controls, mutant (ACHM) retinas show gradual loss 
of cones (labeled red for human cone arrestin, hCAR), preceded by shortening and disruption of their inner and outer segments. There is migration 
of hCAR-labeled cone nuclei into the subretinal space adjacent to the retinal pigment epithelium (arrows, ectopic cone nuclei). Cell nuclei are shown 
in blue with DAPI. *P < 0.05, **P < 0.0001. Calibration bar = 20 µm. Dog fundus drawing reprinted with permission from Dr Kerry Ketring. IS, inner 
segments; T, temporal; N, nasal; OS, outer segments; ONL, outer nuclear layer; OPL, outer plexiform layer.
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Figure 4 Intravitreal CNTF leads to a transient shortening of photoreceptor outer segments in the normal canine retina. Compared with 
PBS-injected control eyes, CNTF causes a uniform shortening of cone (hCAR) and rod (Rho) outer segments at 1 week. This effect was more dramatic 
for the S-cones (S) than for the L/M-cones (L/M) since hardly any labeled S-cone outer segments could be identified at 1 week. At 2 weeks, the pho-
toreceptors appear partially recovered, and are normal at 5 weeks. Cell nuclei are shown in blue with DAPI. Calibration bar = 20 µm. CNTF, ciliary 
neurotrophic factor; hCAR, human cone arrestin; INL, inner nuclear layer; IS, inner segments; L/M, L/M-opsin; ONL, outer nuclear layer; OPL, outer 
plexiform layer; OS, outer segments; S, S-opsin.
Control
hCAR
L/M
S
Rho
1 week 2 weeks 5 weeks
Figure 3 Intravitreal CNTF results in a transient decrease in rod- and cone-mediated ERG responses in normal retina. (a) In comparison with 
intravitreal PBS that had no effect on the ERG (gray traces), intravitreal CNTF (black traces) markedly reduced rod and cone amplitudes. Retinal func-
tion was most severely affected at 1 week, partially restored at 2 weeks, and returned to normal at 5 weeks after injection. (b) Scatterplots showing 
relative ERG amplitudes over time after injection (relative amplitude = amplitude CNTF-treated eye/amplitude contralateral PBS-treated eye). The 
depression of retinal responses was first noted at 3 days after CNTF injection, peaked at 1 week, and recovered to normal by 5 weeks. The linear traces 
connect the median values between each time point. CNTF, ciliary neurotrophic factor; msec, milli second.
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permanently lost (Figure 7). In adult mutants, CNTF treatment 
resulted in cone responses that were similar to, but of lower ampli-
tude, than those recorded from mutant retinas in the early phases 
of postnatal differentiation. We posit that this transient appear-
ance of cone function occurs from partially functional CNGA3 
homotetramer channels that form following the regrowth of cone 
outer segments after CNTF administration.42,43 Indeed, the immu-
nohistochemical evaluation of a CNGB3-mutant retina with par-
tially restored cone-mediated function 1 week following CNTF 
treatment (M635 in Table 1) revealed restoration of weak expres-
sion of both CNGA3 and GNAT2 in some of the deconstructed 
cone outer segments (Supplementary Figure S2).
DISCUSSION
Our present work clearly shows that a combined staged therapy 
of CNTF and rAAV5-PR2.1-hCNGB3 successfully restores cone 
function in two canine models of CNGB3-achromatopsia at older 
ages (14–42 months) when, in the majority of cases, gene aug-
mentation therapy alone cannot. Our data thus provide proof of 
concept for potential CNTF and gene augmentation combina-
tion therapy for restoring cone function in older patients with 
CNGB3-achromatopsia if standard gene augmentation therapy is 
not effective. In addition, understanding the mechanistic basis for 
the CNTF effect will provide essential insights for future under-
standing of the disease progression in CNGB3-achromatopsia, 
and the mechanism that mediates the CNG channel assembly and 
targeting to the cone outer segments.
Although only ~5% of the photoreceptors in the human ret-
ina are cones,44 they are essential for color vision, central visual 
acuity and day vision, and loss of their function leads to severe 
visual dysfunction and impaired quality of life. To this end, we 
have selected achromatopsia, an autosomal-recessive cone visual 
function disorder, as a test platform to develop gene therapy that 
broadly may be applicable to cone-specific diseases. The majority 
of human achromatopsia patients have a channelopathy caused by 
mutations of either the α- or β-subunits of the cone CNG chan-
nels, responsible for the last step in phototransduction.25,26,42,45 The 
present studies were carried out in canine models with either a 
missense mutation in exon 6 or a genomic deletion of CNGB3,27 
both of which are functional nulls based on disease phenotype 
and response to therapy.10 As in human patients with achroma-
topsia,46 the loss of the non-functional cones in canine CNGB3-
achromatopsia is slow, and adequate numbers of cones are present, 
even at advanced ages, to permit functional recovery provided 
treatment is effective. Thus, preclinical studies, including our 
present work on the CNGB3-achromatopsia models, may have 
broad implication not only on treating CNGB3-achromatopsia in 
humans, but also other cone-specific diseases.
Proof of principle studies have demonstrated successful cone-
directed therapy in mouse and canine achromatopsia models 
(mouse: GNAT2,12 CNGA3,13,15 and CNGB3;14 dog: CNGB3).10 
However, despite the very slow cone loss in CNGB3-mutant dogs 
and the successful treatment by gene augmentation in young ani-
mals, treatment with the same therapeutic vector is ineffective in 
animals >1 year.10 Carvalho and colleagues have demonstrated 
a small age effect when assessing outcome of gene therapy in 
CNGB3-mutant mice; there was both a decrease in visual func-
tion and cone ERG amplitude recovery with increasing age at the 
Figure 5 Intravitreal CNTF leads to a transient reduction of photoreceptor-specific gene expression. Relative (a) cone and (b) rod gene expres-
sion measured by qRT-PCR is shown following either intravitreal CNTF or PBS injection compared with a normal biologic control group (n = 3). CNTF 
treatment results in gene expression levels that are ~14–39% of normal for most genes at 1 week. S-cone opsin levels were affected to the greatest 
extent (~0.1% of normal). Expression was comparable with PBS injected eyes by 2 and 5 weeks. CNTF, ciliary neurotrophic factor; qRT-PCR, quantita-
tive real-time PCR.
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time of treatment.14 Similar to the CNGB3-mutant dogs,10 cone 
function was restored in mice up to 6 months of age with gene 
therapy alone.14 Older mice were not treated, and visual acuity 
could not be improved in the 6-month old animals.14 Our pres-
ent work demonstrates that the lack of functional restoration in 
older animals is not due to the loss of cones. Neither is it because 
of lack of therapeutic transgene expression, indicating that viral 
vector tropism and transduction efficiency are not limiting fac-
tors (Komáromy and colleagues10 and present study). Instead, our 
results point to an age-related defect in the ability of the hCNGB3 
transgene protein to either assemble with CNGA3 or promote 
localization of the heterodimeric complexes to the outer segment. 
Alternatively, the deterioration of cone outer segments found in 
some older mutant retinas indicates that those cells are in the early 
stages of degeneration, and not capable of assembling structural 
components of the outer segment.33 The two explanations are not 
mutually exclusive.
As a means of developing a treatment for older animals that 
had adequate numbers of viable cones whose function poten-
tially could be rescued, we used intravitreal bolus administra-
tion of CNTF to transiently deconstruct the mutant cones before 
gene transfer. We reasoned that such treatment could potentially 
“rejuvenate” the cone outer segment, allowing for proper assem-
bly of the membrane subunits of the CNG channel, thereby 
permitting functional recovery following therapy. In support, 
intravitreal bolus administration of CNTF successfully modified 
Figure 6 Intravitreal CNTF injection activates the Jak/Stat pathway in the normal canine retina. (a) Compared with intravitreal PBS, both STAT1 
and STAT3 mRNA expression levels were elevated 1 week after CNTF, remained elevated at 2 weeks, and returned to normal levels at 5 weeks. At the 
protein level, total (b) STAT1 expression was upregulated 1, 2, and 5 weeks after CNTF injection, and both (b) STAT1 and (c) STAT3 became phos-
phorylated 1 week after CNTF. By 2 weeks, the levels had returned to baseline (pSTAT1) or remained slightly elevated (pSTAT3). (d) Both proteins 
were present in the inner margin of the inner nuclear layer, presumably in Müller cells, and in the outer nuclear layer. As with western blots, peak 
expression was at 1 week, and decreased to control levels by 5 weeks. Calibration bar = 20 µm. CNTF, ciliary neurotrophic factor; GCL, ganglion cell 
layer; INL, inner nuclear layer; IPL, inner plexiform layer; NFL, nerve fiber layer; ONL, outer nuclear layer; OPL, outer plexiform layer; PBS, phosphate-
buffered saline; PR, photoreceptors; RPE, retinal pigment epithelium.
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cone cells in the retinas of older mutants which then functioned, 
albeit abnormally, like those of younger mutants. After rAAV-
PR2.1-hCNGB3 treatment, assembled channels were correctly 
targeted to the outer segment, leading to successful functional 
recovery. We posit that deconstruction induced by CNTF, either 
concurrent with or after vector administration, is likely to also 
lead to recovery of cone function. This hypothesis needs to be 
tested experimentally, and investigations are currently underway 
to establish the most effective treatment method. Although our 
current data suggest that the transient photoreceptor decon-
struction may be mediated by the Jak/Stat pathway, the exact 
mechanism leading to the restoration of cone function with 
CNTF treatment in the older animals requires more investiga-
tion. As an example, the use of CNTF could be combined with 
Jak or Stat inhibitors to support or exclude the Jak/Stat pathway 
as a mediator of this finding.
Figure 7 Full-field ERGs recorded from developing CNGB3 mutants, and adult CNGB3 mutants treated with CNTF. (a) Responses recorded from 
a mature wild-type dog for comparison. (b) Responses were comparable during retinal development between the dogs with the genomic deletion 
(CNGB3−/−) and the D262N missense mutation (CNGB3m/m) of CNGB3. Cone-mediated function (oblique arrows) is present at 4 and 6 weeks, but non-
recordable at 8 weeks. Rod function development is normal. (c) CNTF treatment of mutant dogs results in transient recovery of the 1 and 29-Hz cone 
flicker responses (oblique arrows) by 1 week, but these are lost by 5 weeks. Note that intravitreal CNTF results also in dramatic decreases in rod and 
mixed rod-cone response amplitudes. The arrows point to cone-mediated function elicited under light adaptation with single flashes (Cone—1 Hz) or 
fast repeating flashes (Cone—29 Hz). Note that the µV scales are different in c. CNTF, ciliary neurotrophic factor; msec, milli second.
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The partially and transiently restored cone ERG in some of the 
CNGB3-mutant canine retinas with weak expression of CNGA3 
and GNAT2 following CNTF treatment indicates that the photo-
transduction components were at least temporarily reassembled 
in some of the regenerated cone outer segments, providing the 
optimal conditions for successful outcome for gene augmentation. 
Because of the design of our ERG testing protocol, and the equal 
deconstruction of rod and cone outer segments, it is unlikely that 
the observed photopic responses in eyes treated only with CNTF 
were rod mediated rather than cone mediated. The light adapta-
tion levels were more than sufficient to suppress rod signals, and 
the flash frequencies used for 29-Hz flicker stimuli and for averag-
ing of single responses were too fast for rods.
The concept of combining retinal gene augmentation ther-
apy with the application of neurotrophic factors to enhance 
treatment outcome has been used previously as a means of 
delaying photoreceptor cell death prior therapeutic transgene 
expression.47 However, deconstructing and regenerating the 
photoreceptor outer segments in preparation for gene augmen-
tation is a novel concept that may complement more traditional 
approaches when remaining photoreceptors, either rods or 
cones, are refractory to therapy. Future studies are needed to 
examine the broader applicability and molecular mechanisms 
of CNTF-induced photoreceptor deconstruction, and evaluate 
if it allows for improvement of gene therapy outcomes in other 
inherited photoreceptor-specific diseases. As CNTF delivery 
via Encapsulated Cell Technology implants have been tested 
experimentally in animals48 and are undergoing clinical trials 
for age-related macular degeneration and retinitis pigmentosa, 
it is possible that such Encapsulated Cell Technology implants 
combined with therapeutic vectors may further facilitate trans-
lational applications.29
In summary, we have shown that a combination therapy of 
CNTF and gene augmentation can successfully restore cone func-
tion in two CNGB3-achromatopsia dog models when treated 
at older ages when gene therapy alone is ineffective. This novel 
approach could also help in the treatment of other inherited 
photoreceptor-specific diseases. Further studies are needed 
to inform on the molecular mechanism that underlying the 
effects of CNTF in facilitating gene augmentation therapy for 
CNGB3-achromatopsia.
MATERIALS AND METHODS
Animals. Achromatopsia-affected dogs were homozygous for either a 
CNGB3 genomic deletion (CNGB3−/−; n = 7) or a D262N missense muta-
tion (CNGB3m/m; n = 4), both of which result in an identical phenotype.10,27 
To evaluate the effect of intravitreal CNTF injection on the normal retina, 
12 unaffected dogs were used. At the conclusion of the study, the dogs were 
euthanatized with an overdose of euthanasia solution (Euthasol; Virbac, 
Fort Worth, TX), and the eyes enucleated for molecular and histologic 
studies. In addition, eyes were collected from seven mutant dogs and six 
normal controls to determine cone densities and topographic distribu-
tion with disease progression on retinal flat mounts, and for comparison 
of immunohistochemical labeling. Retinal RNA was extracted from the 
eyes of three additional normal, untreated dogs as biologic controls for 
analysis of the qRT-PCR data. All the dogs were part of a research colony 
maintained at the Retinal Disease Studies Facility (Kennett Square, PA) 
and supported by National Eye Institute, NIH (EY-06855) and Foundation 
Fighting Blindness Center grants. The studies were done in accordance 
with the ARVO Statement for the Use of Animals in Ophthalmic and 
Vision Research, and approved by the University of Pennsylvania IACUC.
Recombinant CNTF protein. Recombinant protein was generated by clon-
ing the human CNTF cDNA ORF into expression vector pQE30 (Qiagen, 
Valencia, CA), and expressed in E. coli (XL-blue; Stratagene, La Jolla, CA) 
as previously described.30 The CNTF solution was filtered (Millex-GV 0.22 
µm filter unit; Millipore, Carrigtwohill, Ireland) and stored in 30 µl PBS 
aliquots at −80 °C, each containing 12 µg of CNTF. For control injections, 
sterile 30-µl PBS aliquots were stored at −80 °C.
Vector. The therapeutic vector, rAAV5-PR2.1-hCNGB3, was constructed, 
titered, and purified as previously described.10 This vector provides the 
most robust rescue of cone function in achromatopsia, but only targets the 
canine L/M-cones.10,36 Initially, the vector was injected at concentrations 
of 1.02–4.02 × 1013 vector genomes/ml (vg/ml). Because of mild multifocal 
chorioretinitis and slight retinal thinning in the treatment area, an indica-
tion of vector-associated retinal toxicity,49 the concentration was lowered 
to 7.96 × 1011 vg/ml and all adverse effects prevented.
Intraocular injections. Intravitreal injection of either CNTF (12 µg of 
CNTF in 30 µl of PBS) or PBS (30 µl) was performed under general anes-
thesia (Table 1 and Supplementary Table S1). On the basis of the vitre-
ous volume of adult dogs (2.5–3.0 ml50), the injected dose of CNTF was 
~ 4–5 µg/ml. In 14 eyes of 8 dogs, the intravitreal injection of CNTF or 
PBS was followed 1 week later by the subretinal administration of rAAV5-
PR2.1-hCNGB3 vector (Table 1). Between 120 and 200 µl of vector was 
injected with a RetinaJect subretinal injector (SurModics, Eden Prairie, 
MN) through a transvitreal approach as previously described.10,36 The area 
treated was in the tapetal zone superior to the optic disc, a region with 
higher cone density,34 and was ~25% of the photoreceptor surface area. 
Immediately following surgery, the retinal location and extent of the sub-
retinal blebs were documented by fundus drawings for reference in the 
morphologic studies. Flattening of the subretinal bleb and retinal reattach-
ment occurred within 24–36 hours.
Electroretinography. Standard Ganzfeld scotopic and photopic ERGs were 
recorded from anesthetized dogs using a modified Ganzfeld dome fitted 
with the LED stimuli of a ColorDome stimulator (Diagnosys LLC, Lowell, 
MA).10 Rod and mixed rod-cone–mediated responses were recorded after 
20 minutes of dark adaptation with single white flash stimuli of increasing 
intensities (from 0.000577 to 10.26 cd.seconds/m2). Following 10 minutes 
of light adaptation (34.26 cd/m2), cone-mediated signals were recorded 
to 1-Hz single flash (from 0.00577 to 10.26 cd.seconds/m2) and 29.41-Hz 
flicker (from 0.00577 to 5.77 cd.seconds/m2) stimuli. The combination of 
light adaptation with short flash intervals led to saturation of rods and iso-
lation of pure cone-mediated responses. Except for the brighter scotopic 
light stimuli (≥ 0.577 cd.seconds/m2) multiple responses were averaged.
Retinal morphology and immunohistochemistry. Enucleated eyes were 
fixed for 3 hours in 4% paraformaldehyde followed by 21 hours in 2% para-
formaldehyde, both in 0.1 mol/l PBS at 4 °C. Subsequently, the tissue was 
processed for embedding in optimal cutting temperature medium.11,39,40,49 
Retinas that were only treated by intravitreal CNTF or PBS injections were 
sectioned in the four cardinal meridians through the optic nerve head. 
Retinas that underwent subretinal injections were oriented and sectioned 
based on the location of the treated area to compare treated and untreated 
regions. Cryosections of 10µm were examined by immunohistochemistry 
for protein expression and H&E staining. The primary antibodies and cell 
markers used are detailed in Supplementary Table S2. Six different cus-
tom made canine CNGB3 antibodies were made, but lacked specificity for 
either the canine or human proteins even though they shared sequence 
homology for the targeted epitopes. Alexa Fluor–labeled goat antirabbit 
IgG, donkey antigoat IgG, chicken antimouse IgG, or donkey antimouse 
IgG (1:200; Molecular Probes, Eugene, OR) were used as secondary 
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antibody. For pSTAT1 and pSTAT3 immunohistochemistry, heat-induced 
epitope retrieval was done before overnight incubation with primary anti-
bodies. HRP-labeled goat antirabbit secondary antibodies were used in 
combination with the ABC immunoenzymatic detection method. With 
fluorescence immunohistochemistry, DAPI stain was used as a nuclear 
stain. The In Situ Cell Death Detection kit (Roche Applied Science, 
Indianapolis, IN) was used to visualize apoptotic nuclei following CNTF 
injection by TUNEL (terminal deoxynucleotidyl transferase-mediated 
biotinylated UTP nick end labeling). Sections were examined with a Zeiss 
Axioplan microscope (Carl Zeiss Meditec, Dublin, CA), images were digi-
tally captured (Spot 4.0 camera; Diagnostic Instruments, Sterling Heights, 
MI) and imported into a graphics program (Photoshop; Adobe, Mountain 
View, CA) for display. Selected tissues (Figure 1c and Supplementary 
Figure S2) were imaged by laser scanning confocal microscopy (Olympus 
FluoView FV1000; Olympus America, Center Valley, PA).
The effect of intravitreal delivery of CNTF or PBS on photoreceptor 
ultrastructure was evaluated by electron microscopy 1 week after injection 
in a normal dog. Immediately after enucleation, the posterior segments 
were isolated and fixed, using a triple fixative protocol as previously 
reported.41 The posterior segments were then trimmed, dehydrated, and 
embedded in epoxy resin (PolyBed 812; Polysciences, Warrington, PA). 
Thin sections (70–80 nm) were cut and picked up on Formvar coated 
copper grids, stained with uranyl acetate and lead citrate, and examined 
with a JEOL 1010 electron microscope (JEOL USA, Peabody, MA) fitted 
with a Hamamatsu digital camera (Hamamatsu Corporation, Bridgewater, 
NJ) and AMT Advantage image capture software (Advanced Microscopy 
Techniques, Corp., Woburn, MA).
Mapping of cone photoreceptors in CNGB3-achromatopsia. To deter-
mine the cone density in mutant retinas, selected retinal regions were 
examined in 2 affected and 3 control dogs at 1 year of age. Eyes were col-
lected following euthanasia, fixed between 20 min and 1 h in 4% parafor-
maldehyde in 0.1 mol/l phosphate-buffered saline (PBS) at 4 °C, and each 
retina divided into quadrants along the horizontal and vertical meridians. 
Beginning 2 mm from the optic disc, two consecutive 4-mm circular reti-
nal punches without retinal pigment epithelium were collected with a dis-
posable biopsy punch from each quadrant; these were fixed for 2 hours in 
2% paraformaldehyde in 0.1 mol/l PBS and then stored in PBS at 4 °C for 
immunolabeling with antibodies for S- and L/M-cone opsin and hCAR 
(Supplementary Table S2). Alexa Fluor–labeled goat antirabbit IgG, don-
key antigoat IgG, or chicken antirabbit IgG (1:200; Molecular Probes) 
secondary antibodies were used. The cone subclasses were identified by 
double labeling with either S- or L/M- and hCAR-antibodies. Double-
labeled retinal patches were flat mounted on a glass slide in 0.1 mol/l PBS 
with the photoreceptor outer segments pointing up, cover slipped, and 
sealed with nail polish.
The immunolabeled cone subclasses were imaged within a 2-mm 
diameter circle centered inside each 4-mm retinal trephine using the same 
Zeiss Axioplan microscope (Carl Zeiss Meditec) and Spot 4.0 camera 
(Diagnostic Instruments) as described above. The labeled cone outer 
segments were manually marked on the digital images using Photoshop 
software (Adobe) and counted with image analysis software (MCID 
Analysis version 7.0 grain counting software; Interfocus, Linton, UK).
qRT-PCR analysis of retinal gene expression. Whole retinas were iso-
lated from the eyecups within 1–2 minutes of euthanasia, flash frozen in 
liquid nitrogen, and stored at −80 °C until used. The retinal tissue was 
homogenized, and total RNA extracted with TRIzol Reagent (Invitrogen, 
Life Technologies, Carlsbad, CA). RNA concentrations were determined 
using an ND1000 spectrophotometer (Nanodrop Products, Wilmington, 
DE). Retinal cDNA was synthesized by reverse transcription using the 
High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Life 
Technologies, Carlsbad, CA) and the manufacturer’s instructions. qRT-
PCR was done as previously described using primers and TaqMan MGB 
probes designed for the hCNGB3 transgene, and canine-specific probes for 
cCNGA3, cCNGB3, cL/M-opsin, cS-opsin, cCNGA1, cCNGB1, and cRHO 
(Supplementary Table S3).10 TaqMan expression assays were commercially 
available for STAT1 and STAT3 mRNA (Cf02662970_m1 and Cf02666647_
m1; Applied Biosystems). Relative gene expression for each gene compared 
with the 18S rRNA product (Hs99999901_s1; Applied Biosystems) was cal-
culated as 1/[2^(CtGene − Ct18S)]. Only for the hCNGB3 transgene in retinas 
injected with rAAV5-PR2.1-hCNGB3 was relative gene expression used to 
directly compare CNTF and PBS-treated eyes by unpaired t-test. For all the 
other genes, the ratio of relative gene expressions was calculated between 
the treated eye and an untreated biological control group using the ∆∆CT 
method.38 Any ratio considerably different from 1 was relevant and indi-
cated either an increase (>1) or decrease (<1) of gene expression. Because 
of the small group size for each time point in normal animals undergoing 
intravitreal injections alone, comparisons were made by descriptive statis-
tics. In contrast, the sample sizes were larger for rAAV5-PR2.1-hCNGB3-
treated eyes, allowing the comparison of these gene expression ratios 
between PBS- and CNTF-injected eyes by one-way analysis of variance.
Western blotting. Retinal samples were harvested as described for qRT-
PCR analysis and frozen at −80 °C. The retinas were homogenized in a 
modified RIPA buffer (1% Triton X-100, 1% sodium deoxycholate, 0.1% 
SDS, 158 mmol/l NaCl, and 10 mmol/l Tris) containing a protease inhibi-
tor cocktail (Complete-EDTA; Roche Diagnostics, Indianapolis, IN), fol-
lowed by sonication on ice. The homogenate was centrifuged at 13,000g for 
15 minutes at 4 °C, and the supernatant containing the proteins was col-
lected. Total protein levels were determined by the Bradford method (ABC 
protein assay; Bio-Rad, Hercules, CA). For western blot analysis, 10 µg of 
protein were loaded onto each lane. Membranes were blocked for 1 hour at 
4 °C (Blocking buffer; Li-Cor Biosciences, Lincoln, NE), and incubated for 
1.5 hours at room temperature in primary antibodies pSTAT1 or pSTAT3 
and actin to control for equal loading of each well (Supplementary 
Table  S2). pSTAT1 and pSTAT3 antibodies were detected with a near 
infrared fluorescent goat antirabbit secondary antibody (IRDye 800 CW 
goat antirabbit IgG; Li-Cor Biosciences), and STAT1 and actin antibodies 
with a goat antimouse antibody (IRDye 680 LT goat antimouse IgG; Li-Cor 
Biosciences) diluted to 1:15,000 for 1 hour at room temperature. The bands 
were quantified by densitometry using Odyssey infrared imaging system 
software (Odyssey version 2.1; Li-Cor Biosciences). Detection of STAT3 
levels was performed on a separate blot using the enhanced chemilumi-
nescence technique as we were unsuccessful in detecting both pSTAT3 and 
STAT3 antibodies with the Odyssey technique on the same blot. Levels 
of STAT3 and pSTAT3 were normalized to actin before calculating the 
pSTAT3/STAT3 ratio.
SUPPLEMENTARY MATERIAL
Figure S1. Electron micrographs of normal canine retinas 1 week fol-
lowing intravitreal injection of PBS or CNTF.
Figure S2. Partial restoration of CNGA3 and GNAT2 protein localiza-
tion in the CNGB3-mutant retina 1 week following intravitreal CNTF 
injection.
Table S1. Intravitreal CNTF injections in normal dogs.
Table S2. Antibodies and reagents used for immunohistochemistry 
and western blotting.
Table S3. Primers and probes for qRT-PCR and exon junction crossed 
by PCR product.
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